TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of “Moderate Buy” by Analysts

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has been given an average rating of “Moderate Buy” by the five research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $10.50.

TLSI has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Friday, November 28th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Nantahala Capital Management LLC boosted its holdings in TriSalus Life Sciences by 2.0% in the third quarter. Nantahala Capital Management LLC now owns 2,040,245 shares of the company’s stock valued at $9,487,000 after purchasing an additional 40,245 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $6,812,000. Vanguard Group Inc. raised its position in shares of TriSalus Life Sciences by 42.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after purchasing an additional 345,186 shares in the last quarter. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of TriSalus Life Sciences by 32.1% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after buying an additional 265,618 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of TriSalus Life Sciences by 107.4% during the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock valued at $2,480,000 after buying an additional 235,627 shares during the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Stock Performance

TLSI stock opened at $6.43 on Thursday. The firm has a market cap of $321.24 million, a P/E ratio of -3.18 and a beta of 0.43. TriSalus Life Sciences has a 1 year low of $3.42 and a 1 year high of $7.32. The stock has a 50-day simple moving average of $4.97 and a 200-day simple moving average of $4.94.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.79). The business had revenue of $11.57 million during the quarter, compared to analysts’ expectations of $11.76 million. On average, equities research analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current year.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.